{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:14:05Z","timestamp":1794003245833,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2025JJ90128"],"award-info":[{"award-number":["2025JJ90128"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001489"],"award-info":[{"award-number":["82001489"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471623"],"award-info":[{"award-number":["82471623"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010482"],"award-info":[{"award-number":["2025A1515010482"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["NSZD2023041"],"award-info":[{"award-number":["NSZD2023041"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["KJZD20240903103500002"],"award-info":[{"award-number":["KJZD20240903103500002"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016804","name":"Natural Science Foundation of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20240813114423031"],"award-info":[{"award-number":["JCYJ20240813114423031"]}],"id":[{"id":"10.13039\/100016804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202303037"],"award-info":[{"award-number":["SZSM202303037"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.metabol.2025.156485","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:06:02Z","timestamp":1766534762000},"page":"156485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo"],"prefix":"10.1016","volume":"176","author":[{"given":"Gang","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.metabol.2025.156485_bb0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.metabol.2025.156485_bb0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The Multifaceted Biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"issue":"16","key":"10.1016\/j.metabol.2025.156485_bb0015","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.metabol.2025.156485_bb0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.metabol.2025.156485_bb0025","doi-asserted-by":"crossref","first-page":"15513","DOI":"10.1021\/acs.jmedchem.2c01290","article-title":"Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment","volume":"65","author":"Ahamad","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacl.2019.10.015","article-title":"ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"Spec Feature","key":"10.1016\/j.metabol.2025.156485_bb0040","first-page":"136","article-title":"Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.metabol.2025.156485_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154342","article-title":"Novel triterpenoids from Alisma plantago-aquatica with influence on LDL uptake in HepG2 cells by inhibiting PCSK9","volume":"105","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.metabol.2025.156485_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108812","article-title":"Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?","volume":"268","author":"Corsini","year":"2025","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.metabol.2025.156485_bb0060","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11883-022-01053-3","article-title":"PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid-Based Therapy Era","volume":"24","author":"Gouni-Berthold","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"issue":"6","key":"10.1016\/j.metabol.2025.156485_bb0065","article-title":"Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats\/Cas in Gene Therapies","volume":"12","author":"Banda","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.metabol.2025.156485_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13808","article-title":"Prime editing: a revolutionary technology for precise treatment of genetic disorders","volume":"58","author":"Li","year":"2025","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.metabol.2025.156485_bb0080","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1087057110365897","article-title":"A review of methods to monitor the modulation of mRNA stability: a novel approach to drug discovery and therapeutic intervention","volume":"15","author":"Cheneval","year":"2010","journal-title":"J. Biomol. Screen."},{"issue":"24","key":"10.1016\/j.metabol.2025.156485_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27248828","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy: present and future","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.metabol.2025.156485_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28031217","article-title":"PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities","volume":"28","author":"Liu","year":"2023","journal-title":"Molecules"},{"issue":"24","key":"10.1016\/j.metabol.2025.156485_bb0095","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/cmdc.202000574","article-title":"Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin","volume":"15","author":"Verheul","year":"2020","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.metabol.2025.156485_bb0100","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1039\/C9MD00263D","article-title":"Emerging modes-of-action in drug discovery","volume":"10","author":"Valeur","year":"2019","journal-title":"Medchemcomm"},{"issue":"17","key":"10.1016\/j.metabol.2025.156485_bb0105","article-title":"In situ self-assembly of artificial topological nanostructures enhances in vivo efficacy of PCSK9 inhibitory peptides","volume":"64","author":"Li","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"22","key":"10.1016\/j.metabol.2025.156485_bb0110","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.metabol.2025.156485_bb0115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41419-024-07073-y","article-title":"Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates","volume":"15","author":"Shi","year":"2024","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.metabol.2025.156485_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020600","article-title":"A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future","volume":"15","author":"Holz","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.metabol.2025.156485_bb0125","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1021\/jacs.4c00314","article-title":"Inverse Peptide Synthesis Using Transient Protected Amino Acids","volume":"146","author":"Liu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"15","key":"10.1016\/j.metabol.2025.156485_bb0130","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1021\/acs.jmedchem.0c02051","article-title":"Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9","volume":"64","author":"Bourbiaux","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.metabol.2025.156485_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05375-7","article-title":"High-potency PD-1\/PD-L1 degradation induced by peptide-PROTAC in human cancer cells","volume":"13","author":"Dai","year":"2022","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.metabol.2025.156485_bb0140","doi-asserted-by":"crossref","first-page":"10336","DOI":"10.1021\/acs.jmedchem.4c00828","article-title":"A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1\u20133","key":"10.1016\/j.metabol.2025.156485_bb0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14779072.2023.2288169","article-title":"PCSK9 inhibitors: current status and emerging frontiers in lipid control","volume":"22","author":"Agnello","year":"2024","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.metabol.2025.156485_bb0155","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/ATVBAHA.122.317963","article-title":"New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing","volume":"43","author":"Oostveen","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.metabol.2025.156485_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237964","article-title":"A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.metabol.2025.156485_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/genes14030632","article-title":"Interplay between microRNAs, Serum Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors","volume":"14","author":"Levstek","year":"2023","journal-title":"Genes (Basel)"},{"issue":"14","key":"10.1016\/j.metabol.2025.156485_bb0170","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jacc.2021.07.056","article-title":"Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies","volume":"78","author":"Oleaga","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.metabol.2025.156485_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155774","article-title":"Inhibition of PCSK9 prevents and alleviates cholesterol gallstones through PPARalpha-mediated CYP7A1 activation","volume":"152","author":"Chen","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2025.156485_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154577","article-title":"Tilianin improves lipid profile and alleviates atherosclerosis in ApoE(\u2212\/\u2212) mice through up-regulation of SREBP2-mediated LDLR expression","volume":"109","author":"Du","year":"2023","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.metabol.2025.156485_bb0185","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.tem.2018.03.013","article-title":"Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?","volume":"29","author":"Dijk","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.metabol.2025.156485_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2018.01.025","article-title":"Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps","volume":"130","author":"Baragetti","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.metabol.2025.156485_bb0195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2021.06.903","article-title":"The emerging landscape of peptide-based inhibitors of PCSK9","volume":"330","author":"Tombling","year":"2021","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.metabol.2025.156485_bb0200","doi-asserted-by":"crossref","first-page":"8978","DOI":"10.1021\/acsabm.0c01229","article-title":"Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides","volume":"3","author":"Harbour","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"issue":"22","key":"10.1016\/j.metabol.2025.156485_bb0205","doi-asserted-by":"crossref","first-page":"13796","DOI":"10.1021\/acs.jmedchem.0c01084","article-title":"Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design","volume":"63","author":"Alleyne","year":"2020","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.metabol.2025.156485_bb0210","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/cbic.202100103","article-title":"Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9)","volume":"22","author":"Tombling","year":"2021","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.jmedchem.3c01634","article-title":"Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds","volume":"67","author":"Ouyang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chembiol.2019.10.002","article-title":"From screening to targeted degradation: strategies for the discovery and optimization of small molecule ligands for PCSK9","volume":"27","author":"Petrilli","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.metabol.2025.156485_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156064","article-title":"PCSK9 in metabolism and diseases","volume":"163","author":"Ajoolabady","year":"2025","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2025.156485_bb0230","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/ATVBAHA.118.311241","article-title":"STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia","volume":"38","author":"Cansby","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.metabol.2025.156485_bb0235","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1021\/acs.jmedchem.3c00013","article-title":"Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.metabol.2025.156485_bb0240","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.7150\/thno.75444","article-title":"Design of stapled peptide-based PROTACs for MDM2\/MDMX atypical degradation and tumor suppression","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.metabol.2025.156485_bb0245","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low-density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.metabol.2025.156485_bb0250","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.7150\/thno.41677","article-title":"A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.metabol.2025.156485_bb0255","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40824-023-00385-8","article-title":"Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)","volume":"27","author":"Wang","year":"2023","journal-title":"Biomater Res"},{"issue":"5","key":"10.1016\/j.metabol.2025.156485_bb0260","article-title":"Self-assembled peptide-derived proteolysis-targeting chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in cancer immunotherapy","volume":"64","author":"Moon","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"21","key":"10.1016\/j.metabol.2025.156485_bb0265","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-23-0025","article-title":"Matrix Stiffness Triggers Lipid Metabolic Cross-talk between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases","volume":"83","author":"Zheng","year":"2023","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.metabol.2025.156485_bb0270","article-title":"Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv Sci (Weinh)"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:12:14Z","timestamp":1778649134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525003555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["S0026049525003555"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156485","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156485"}}